Van der Oord 2007.

Methods	A 4‐week pseudorandomised, placebo‐controlled, cross‐over study investigating the additional value of short‐term intensive multimodal behaviour therapy to optimally titrated methylphenidate Follow‐up 4.5 to 7.5 years after treatment
Participants	Number of participants screened: not stated Number of participants included in methylphenidate group: 23; included in methylphenidate + multimodal behaviour therapy: 27 Number of participants followed up in methylphenidate group: 21 Number of withdrawals in methylphenidate group: 2 Diagnosis of ADHD: DSM‐IV/I (subtype: combined (n = 31), hyperactive‐impulsive (n = 3), inattentive (n = 16)) Age: mean 9.6 years old IQ: 96.81 Sex: not stated Methylphenidate‐naïve: 100% Ethnicity: white: 89%, others: 11% Country: Netherlands Setting: Comorbidity: oppositional defiant disorder/conduct disorder 61.9%, oppositional defiant disorder 46%, conduct disorder 4% Comedication: no Sociodemographics: most parents medium to high education level Inclusion criteria: ADHD according to DSM‐IV Full scale IQ above 75 (WISC‐R) Exclusion criteria: Inadequate mastering of Dutch language by the child or both parents A history of methylphenidate use
Interventions	Methylphenidate type: not stated Methylphenidate dosage: 5 mg, 10 mg, and 20 mg in titration period Administration schedule: 7:30 am, 12:30 pm Duration of intervention: 4 week pseudo randomised cross‐over design, 1 week medication‐free, 5 weeks optimal dose Treatment compliance: high, weekly phone calls to parents and teachers
Outcomes	The MTA Side Effect Rating Scale was used to assess side effects
Notes	Sample calculation: yes (power calculation) Ethics approval: not stated Funding: not stated Vested interest/authors' affiliations: not stated Key conclusions of the study authors: no evidence was found for the additive effect of multimodal behaviour therapy next to optimally titrated methylphenidate Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: no Supplemental information regarding data on adverse events received through personal email correspondence with the authors in January 2014 (Van der Oord 2014 [pers comm])